Proactive Investors - Run By Investors For Investors

MaxCyte extends relationship with Gilead Sciences-owned cancer drug developer Kite

Kite will use MaxCyte's Flow Electroporation cell engineering platform to help it develop “multiple” CAR-T drug candidates for up to ten targets
cell engineering
This latest agreement builds on a deal announced last November

Life sciences group MaxCyte Inc (LON:MXCT) has extended its relationship with Kite – the multi-billion-dollar cancer drug developer owned by US giant Gilead Sciences.

Under the terms of this latest agreement, Kite will use MaxCyte’s Flow Electroporation technology to help it develop “multiple” CAR-T drug candidates for up to ten targets.

READ: MaxCyte inks research agreement with Gilead subsidiary Kite Pharma

“We're excited to take our relationship with Kite further into product development, providing the company with the ability to leverage MaxCyte's versatile cell engineering platform to enable the power of gene-editing for clinical and commercial development of critical new CAR-T therapeutics,” said MaxCyte president and chief executive Doug Doerfler.

In CAR-T, patient immune cells are extracted, genetically modified with a receptor to target certain cancer cells, then reinfused back into the patient.

This is where MaxCyte’s technology comes in: it allows almost any molecule – such as DNA, RNA or proteins – to be delivered into any cell with minimal cell disturbance.

In return for granting Kite the non-exclusive rights to use its cell engineering platform, Maryland, US-based MaxCyte will receive development and approval milestones and sales-based payments, as well as other licensing fees.

The expansion of the Kite-MaxCyte relationship builds on an existing research agreement announced in November 2018.

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY TO US PERSONS, AS DEFINED IN REGULATIONS PROMULGATED UNDER THE US SECURITIES ACT 1933, AS AMENDED (THE “US SECURITIES ACT”), OR IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE OR PUBLICATION WOULD BE UNLAWFUL.”
View full MXCT profile View Profile

MaxCyte Timeline

Related Articles

1557403923_iron.jpg
May 09 2019
Here we take a look under the hood of Shield Therapeutics
Empty lab
September 19 2018
Management has made some tough decisions, cutting the cost base, since a disappointing first-half performance and expects the benefits to really kick in next year
test tubes
April 16 2019
Summit Therapeutics' potential breakthrough targets C.difficile

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use